NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/24/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization39.99 mln
Float1.24 mln
Earnings Date12/22/2026
Piotroski F-Score
4
/ 9
Borderline
Relative Strength
36
/ 100
Underperforming
Debt / Equity
-0.20
Negative equity
ROE
-1,305
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Apollomics is a drug development company focused on finding new treatments for cancer. Founded in 2015 and based in Foster City, California, the company is currently testing several experimental medicines in clinical trials, targeting the biological signals that allow cancer cells to grow and spread. Its most advanced candidate, Vebreltinib, is in Phase 2 trials for lung cancer and other solid tumors, while additional treatments targeting brain cancer and other tumor types are in earlier stages of testing.
